在携带点突变的遗传性非息肉病性结直肠癌(HNPCC)患者中,MSH2、MLH1或MSH6中的基因组重排很少见。

Genomic rearrangements in MSH2, MLH1 or MSH6 are rare in HNPCC patients carrying point mutations.

作者信息

Pistorius Steffen, Görgens Heike, Plaschke Jens, Hoehl Ruth, Krüger Stefan, Engel Christoph, Saeger Hans-Detlev, Schackert Hans K

机构信息

Department of Visceral, Thoracic and Vascular Surgery, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany.

出版信息

Cancer Lett. 2007 Apr 8;248(1):89-95. doi: 10.1016/j.canlet.2006.06.002. Epub 2006 Jul 11.

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominant disease with high penetrance, caused by germline mutations in the mismatch repair (MMR) genes MLH1, MSH2, MSH6, PMS2 and MLH3. Most reported pathogenic mutations are point mutations, comprising single base substitutions, small insertions and deletions. In addition, genomic rearrangements, such as large deletions and duplications not detectable by PCR and Sanger sequencing, have been identified in a significant proportion of HNPCC families, which do not carry a pathogenic MMR gene point mutation. To clarify whether genomic rearrangements in MLH1, MSH2 or MSH6 also occur in patients carrying a point mutation, we subjected normal tissue DNA of 137 colorectal cancer (CRC) patients to multiplex ligation-dependent probe amplification (MLPA) analysis. Patients fulfilled the following pre-requisites: all patients met at least one criterion of the Bethesda guidelines and their tumors exhibited high microsatellite instability (MSI-H) and/or showed loss of expression of MLH1, MSH2 or MSH6 proteins. PCR amplification and Sanger sequencing of all exons of at least one MMR gene, whose protein expression had been lost in the tumor tissue, identified 52 index patients without a point mutation (Group 1), 71 index patients with a pathogenic point mutation in MLH1 (n=38) or MSH2 (n=22) or MSH6 (n=11) (Group 2) and 14 patients with an unclassified variant in MLH1 (n=9) or MSH2 (n=3) or MSH6 (n=2) (Group 3). In 13 of 52 patients of group 1 deletions of at least one exon were identified. In addition, in group 3 one EX1_15del in MLH1 was found. No genomic rearrangement was identified in group 2 patients. Genomic rearrangements represent a significant proportion of pathogenic mutations of MMR genes in HNPCC patients. However, genomic rearrangements are rare in patients carrying point mutations in MMR genes. These findings suggest the use of genomic rearrangement tests in addition to Sanger sequencing in HNPCC patients.

摘要

遗传性非息肉病性结直肠癌(HNPCC)是一种常染色体显性疾病,具有高外显率,由错配修复(MMR)基因MLH1、MSH2、MSH6、PMS2和MLH3中的种系突变引起。大多数报道的致病突变是点突变,包括单碱基替换、小插入和缺失。此外,在相当一部分未携带致病MMR基因点突变的HNPCC家族中,已鉴定出基因组重排,如无法通过PCR和桑格测序检测到的大片段缺失和重复。为了明确携带点突变的患者中MLH1、MSH2或MSH6是否也会发生基因组重排,我们对137例结直肠癌(CRC)患者的正常组织DNA进行了多重连接依赖探针扩增(MLPA)分析。患者满足以下先决条件:所有患者至少符合贝塞斯达指南的一项标准,且其肿瘤表现出高微卫星不稳定性(MSI-H)和/或显示MLH1、MSH2或MSH6蛋白表达缺失。对至少一个MMR基因的所有外显子进行PCR扩增和桑格测序,这些外显子在肿瘤组织中的蛋白表达缺失,共鉴定出52例无点突变的索引患者(第1组)、71例在MLH1(n = 38)或MSH2(n = 22)或MSH6(n = 11)中有致病点突变的索引患者(第2组)和14例在MLH1(n = 9)或MSH2(n = 3)或MSH6(n = 2)中有未分类变异的患者(第3组)。在第1组的52例患者中,有13例鉴定出至少一个外显子缺失。此外,在第3组中发现了1例MLH1中的EX1_15del。在第2组患者中未鉴定出基因组重排。基因组重排在HNPCC患者的MMR基因致病突变中占相当比例。然而,在携带MMR基因点突变的患者中,基因组重排很少见。这些发现表明,除了对HNPCC患者进行桑格测序外,还应使用基因组重排检测。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索